Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 6723807, 8 pages
http://dx.doi.org/10.1155/2016/6723807
Research Article

Combinatorial Antitumor Effect of Rapamycin and β-Elemene in Follicular Thyroid Cancer Cells

1School of Medicine, Taizhou University, Taizhou, Zhejiang 318000, China
2Taizhou Enze Hospital, Taizhou, Zhejiang 318000, China
3Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, China
4School of Pharmaceutical and Chemical Engineering, Taizhou University, Taizhou, Zhejiang 318000, China
5Institute of Tumor, Taizhou University, Taizhou, Zhejiang 318000, China

Received 24 December 2015; Revised 21 March 2016; Accepted 10 April 2016

Academic Editor: Goutam Ghosh Choudhury

Copyright © 2016 Jun Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Goldstein, A. B. Patel, J. L. Curry, V. Subbiah, and S. Piha-Paul, “Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report,” BMC Dermatology, vol. 15, article 2, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. S.-F. Lin, Y.-Y. Huang, J.-D. Lin, T.-C. Chou, C. Hsueh, and R. J. Wong, “Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy,” PLoS ONE, vol. 7, no. 10, Article ID e46726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. G. I. Manfredi, A. Dicitore, G. Gaudenzi, M. Caraglia, L. Persani, and G. Vitale, “PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy,” Endocrine, vol. 48, no. 2, pp. 363–370, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Papewalis, M. Wuttke, S. Schinner et al., “Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer,” Hormone and Metabolic Research, vol. 41, no. 10, pp. 752–756, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. E. C. L. de Souza, A. C. F. Ferreira, and D. P. de Carvalho, “The mTOR protein as a target in thyroid cancer,” Expert Opinion on Therapeutic Targets, vol. 15, no. 9, pp. 1099–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Laplante and D. M. Sabatini, “mTOR signaling in growth control and disease,” Cell, vol. 149, no. 2, pp. 274–293, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Xia and X. Y. Xu, “PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application,” American Journal of Cancer Research, vol. 5, no. 5, pp. 1602–1609, 2015. View at Google Scholar
  8. X. Wan and L. J. Helman, “The biology behind mTOR inhibition in sarcoma,” Oncologist, vol. 12, no. 8, pp. 1007–1018, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. Y.-Y. Zhou, H.-X. Liu, N. Jiang et al., “Elemene, the essential oil of Curcuma wenyujin, inhibits osteogenic differentiation in ankylosing spondylitis,” Joint Bone Spine, vol. 82, no. 2, pp. 100–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. Q. Li, G. Wang, H. Liang et al., “β-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas,” Anticancer Research, vol. 33, no. 4, pp. 1421–1428, 2013. View at Google Scholar · View at Scopus
  11. Q. Q. Li, R. X. Lee, H. Liang, and Y. Zhong, “Anticancer activity of β-elemene and its synthetic analogs in human malignant brain tumor cells,” Anticancer Research, vol. 33, no. 1, pp. 65–76, 2013. View at Google Scholar · View at Scopus
  12. Q. Q. Li, R. X. Lee, H. Liang et al., “β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK,” International Journal of Oncology, vol. 43, no. 3, pp. 721–728, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. Hu, H. Wu, Y. Li et al., “β-Elemene inhibits the proliferation of esophageal squamous cell carcinoma by regulating long noncoding RNA-mediated inhibition of hTERT expression,” Anti-Cancer Drugs, vol. 26, no. 5, pp. 531–539, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L. J. Helman, “Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism,” Oncogene, vol. 26, no. 13, pp. 1932–1940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Shi, H. Yan, P. Frost, J. Gera, and A. Lichtenstein, “Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade,” Molecular Cancer Therapeutics, vol. 4, no. 10, pp. 1533–1540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. X.-G. Chen, F. Liu, X.-F. Song et al., “Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways,” Molecular Carcinogenesis, vol. 49, no. 6, pp. 603–610, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Gupta, S. M. Ansell, A. J. Novak, S. Kumar, S. H. Kaufmann, and T. E. Witzig, “Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2,” Blood, vol. 114, no. 14, pp. 2926–2935, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Mi, Q. Ye, S. Liu, and Q.-B. She, “AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis,” Oncotarget, vol. 6, no. 16, pp. 13962–13977, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. H. Zhan, J. Liu, X. J. Qu et al., “β-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of mAPK/ERK and PI3K/Akt/mtor signalling pathways,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 6, pp. 2739–2744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. A. Patel, M. A. Dave, S. A. Bliss et al., “Treg/Th17 polarization by distinct subsets of breast cancer cells is dictated by the interaction with mesenchymal stem cells,” Journal of Cancer Stem Cell Research, vol. 2014, no. 2, p. e1003, 2014. View at Google Scholar
  21. H. Wu, K. Wang, G. Li et al., “Effects of transcutaneous acupoint electrical stimulation on the imbalance of Th1, Th2, Th17 and Treg cells following thoracotomy of patients with lung cancer,” Experimental and Therapeutic Medicine, vol. 11, no. 2, pp. 495–502, 2016. View at Publisher · View at Google Scholar
  22. L. Islas-Vazquez, H. Prado-Garcia, D. Aguilar-Cazares et al., “LAP TGF-β subset of CD4+CD25+CD127- treg cells is increased and overexpresses LAP TGF-β in lung adenocarcinoma patients,” BioMed Research International, vol. 2015, Article ID 430943, 11 pages, 2015. View at Publisher · View at Google Scholar
  23. X. Wang, L. Wang, Q. Mo, Y. Dong, G. Wang, and A. Jia, “Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 5, pp. 5702–5708, 2015. View at Google Scholar · View at Scopus
  24. H. Kopf, G. M. de la Rosa, O. M. Z. Howard, and X. Chen, “Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells,” International Immunopharmacology, vol. 7, no. 13, pp. 1819–1824, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Quek, Q. Wang, J. A. Morgan et al., “Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors,” Clinical Cancer Research, vol. 17, no. 4, pp. 871–879, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Doherty, D. C. Gigas, S. Kesari et al., “Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas,” Neurology, vol. 67, no. 1, pp. 156–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Awada, F. Cardoso, C. Fontaine et al., “The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics,” European Journal of Cancer, vol. 44, no. 1, pp. 84–91, 2008. View at Publisher · View at Google Scholar · View at Scopus